Actinomycetes and drug-an overview

American Journal of Drug Discovery and Development

Volumn 1, Issue 2, 2011, Pages 75-84

  Raja, A ^a   Prabakarana, P ^b  

^a JAMAL MOHAMED COLLEGE   (India)

^b PRIST UNIVERSITY   (India)

Author keywords

Actinobacteria; Antibiotics; FDA; Metabolites

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMRUBICIN; ANTIINFECTIVE AGENT; BIAPENEM; BLEOMYCIN; BROSTALLICIN; CHLORAMPHENICOL; DACTINOMYCIN; DAPTOMYCIN; DAUNORUBICIN; DOXORUBICIN; ELSAMICIN A; ERTAPENEM; ERYTHROMYCIN; EVEROLIMUS; GEMTUZUMAB OZOGAMICIN; IVERMECTIN; MACROLIDE; MIGLUSTAT; MITHRAMYCIN; MITOMYCIN; PIMECROLIMUS; RIFAMYCIN DERIVATIVE; STREPTOMYCIN DERIVATIVE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; THIENAMYCIN; TIGECYCLINE; VANCOMYCIN;

ACTINOBACTERIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; BREAST CANCER; DRUG APPROVAL; DRUG INDUSTRY; DRUG ISOLATION; DRUG MECHANISM; LEUKEMIA; LEWIS CARCINOMA; LUNG CANCER; METABOLITE; MYCELIUM; NONHUMAN; REVIEW; SARCOMA; STOMACH CANCER; STREPTOMYCES;

EID: 79957612521     PISSN: 2150427X     EISSN: 21504296     Source Type: Journal    
DOI: 10.3923/ajdd.2011.75.84     Document Type: Review

References (27)

1. Birnbaum, J., F.M. Kahan, H. Kropp and J.S. MacDonald, 1985. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am. J. Med., 78: 3-21.
2. Bisht, K.S., M. Bradbury, D. Mattson, A. Kaushal and A. Sowers et al., 2003. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res., 63: 8984-8995.
3. Broggini, M., S. Marchini, E. Fontana, D. Moneta, C. Fowst and C. Geroni, 2004. Brostacillin: A new concept in minor groove DNAbinder development. Anticancer Drugs, 15: 1-6.
4. Chapman, T.M. and CM. Perry, 2004. Everohmus. Drugs, 64: 861-872.
5. Czerepak, E.A. and S. Ryser, 2005. Drug approvals and failures: Implications for alliances. Nat. Rev. Drug Discovery, 7: 197-198.
6. Donadio, S., L. Carrano, L. Brandi, S. Serina and A. Soffientini et al., 2002a. Targets and assays for discovering novel antibacterial agents. J. Biotechnol., 99: 175-185.
7. Donadio, S., P. Monciardini, R. Alduina, P. Mazza and C. Chiocchini et al., 2002b. Microbial technologies or the discovery of novel bioactive metabolites. J. Biotechnol., 99: 187-198.
8. Euzeby, J. P., 2008. Genus streptomyces. List of Prokaryotic names with Standing in Nomenclature. http://www.bacterio.cict.fr/s/streptomycesa.html.
9. Fenton, C, G.M. Keating and M.P. Curran, 2004. Daptomycm. Drugs, 64: 445-455.
10. Geroni, C, S. Marchini and P. Cozzi, 2002. Brostalicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res., 62: 2332-2336.
11. Gupta, A.K. and M. Chow, 2003. Pimecrolimus: A review. J. Eur. Acad. Dermatol. Venereol., 17: 493-503.
12. Hoskeri, H.J., V. Krishna and C. Amruthavalli, 2010. Effects of extracts from lichen Ramalinapacifica against clinically infectious bacteria. Researcher, 2: 81-85.
13. Kampfer, P., 2006. The Family Streptomycetaceae, Part I: Taxonomy. In: The Prokaryotes: A Handbook on the Biology of Bacteria, Dworkin, M. (Eds.). Springer, Berlin, pp: 538-604.
14. Kieser, T., M.J. Bibb, M.J. Buttner, K.F. Chater and D.A. Hopwood, 2000. Practical Streptomyces Genetics. John Innes Foundation, Norwich, England, ISBN 0-7084-0623-8.
15. Lee, M.D, T.S. Dunne, M.M. Siegel, C.C. Chang, G.O. Morton and D.B. Borders, 1987. Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure ofcahchemicm. J. Am. Chem. Soc, 109: 3464-3466.
16. Madigan, M. and J. Martinko, 2005. Brock Biology of Microorganisms. 11th Edn., Prentice Hall, New Jersey, USA.
17. Pastores, G.M., N.L. Barnett and E.H. Kolodny, 2005. An open-label, non comparative study of miglustat in type I Gaucher disease: Efficacy and tolerability over 24 months of treatment. Clin. Ther, 27: 1215-1227.
18. Perry, CM. and T. Ibbotson, 2002. Biapenem. Drugs, 62: 2221-2234.
19. Portugal, J., 2003. Chartreusin, elsamicin A and related anti-cancer antibiotics. Curr. Med. Chem. Anticancer Agents, 3: 411-420.
20. Raja, A., P. Prabakaran and P. Gajalakshmi, 2010a. Isolation and screening of antibiotic producing psychrophilic actinomycetes and its nature from rothang hill soil against viridans Streptococcus sp. Res. J. Microbiol., 5: 44-49.
21. Raja, A., P. Prabakaran, P. Gajalakshmi and A.H. Rahman 2010b. A population study of psychrophilic actinomycetes isolated from rothang hill-manali soil sample. J. Pure Applied Microbiol, 4:847-851.
22. Sader, H.S. and A.C. Gales, 2001. Emerging strategies in infectious diseases: New carbapenem and trinem antibacterial agents. Drugs, 61: 553-564.
23. Sasaki, K, K.L. Rinehart Jr., G. Slomp, M.F. Grostic and B.C. Olson, 1970. Geldanamycin. I. Structure assignment. J. Am. Chem. Soc, 92: 7591-7593.
24. Sugiura, T, Y. Ariyoshi, S. Negoro, S. Nakamura and H. Ikegami etal., 2005. Phase I/II study of amrubicin, a novel 9-aminoanthracycline, in patients with advanced non-small-cell lung cancer. Invest. New Drugs, 23: 331-337.
25. Todar, K, 2009. Antimicrobial agents in the treatment of infectious disease. Todars Online TextBook of Bacteriology, http://www.textbookofbacteriology.net/antimicrobial.html.
26. Zhanel, G. G, M. Walters, A. Noreddin, L. M. Vercaigne and A. Wierzbowskix etal., 2002. ketolides: A critical review. Drugs, 62: 1771-1804.
27. Zhanel, G.G, K. Homenuick, A. Noveddin, K. Nichol and L. Vercaigne et al., 2004. The glycyclines: A comparative review with the tetracyclines. Drugs, 64: 63-88.